

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170009032				
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)				
Palabras clave utilizadas		HEPATITIS B VIRAL INFECTION; TOLL-LIKE RECEPTOR; 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07D 471/04, A61K 31/519, A61P 29/00, A61P 31/12, A61P 35/00, A61P 37/00. CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ORBIT; ESPACENET, EPOQUENET y USPTO	WO2012156498	22/Noviembre/2012	1 a 32 NIVEL INVENTIVO	X,Y
	WO2008077649	03/Julio/2008	1 a 32 NIVEL INVENTIVO	X,Y
** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.			“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.	

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	--
Fecha del reporte de búsqueda:	28/11/2018

ORBIT

Erase all Save entire strategy Create a script Export Menu Explorer					
Patent family searches (FamPat)					
Search Step	Result(s)	Query	Assistant	Source	Action
28	14	25 AND 26 AND 27	Search history	FAMPAT	Show results Modify Save Alert Delete
27	31996	PYRIMIDINE	Search history	FAMPAT	Show results Modify Save Alert Delete
26	1460	(TOLL_LIKE S RECEPTOR)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
25	2107	(HEPATITIS S B S VIRAL S INFECTION)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete

Easy search Save strategy

Menu **Filter** Explorer << >> Preview ⁽⁹⁾ Image ⁽⁹⁾

Filter options ^(?)

1st application year

- After 2015 (9)
- 2011-2015 (4)
- 2006-2010 (1)
- 2001-2005 (0)
- Before 2001 (0)

Assignee

- HOFFMANN LA ROCHE (5)
- CHIA TAI TIANQING PHARMACEUTICAL (3)
- ROCHE (2)
- 3M (1)
- APROS THERAPEUTICS (1)
- More...

Litigations


Oppositions

IPC classification


US classification

14 results for 25 AND 26 AND 27 - Collection: FAMPAT

Select Family grouping Display Translate Edit Preview

#	TI	PN	1st app. date	PA	CIDL_OP	PD
1	4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors	BR102016004764	2016-03-02	GILEAD SCIENCES* GILLIARD SCIENCES		2016
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2-d] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. 						
2	Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis	WO2009067081	2008-11-18	ASTRAZENECA* ASTRAZENECA ACTEERBORG ASTRAZENECA ASTRAZENECA AKTIEBOLAG DAINIPPON SUMITOMO PHARMA*		2009
The present invention provides compounds of formula (I) wherein R 1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 						
3	Pyrimidine compounds containing	US20180155298	2017-12-04	APROS		2018

4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors



ESPACENET

Cited in	International search
	[XY]* WO2012156498 (JANSSEN R & D IRELAND [IE], et al) [X] 1,3-20,63-71,74-102 * Various compounds of the table on pages 70ff, e.g. compound 8, 9, 13, 16, 72-85,87-89;; claim - * [Y] 2,21-62,72,73;
	[XDY]* WO2014076221 (JANSSEN R & D IRELAND [IE]) [XD] 1,3-20,63-71,74-102 * Compounds of table II on page 15; Data of table VI on page 27;; claims 1-4 * [Y] 2,21-62,72,73;
	[X]* WO2008077649 (GILEAD SCIENCES INC [US], et al) [X] 1-102 * The 6-chloro-N4-(2-methanesulfonyl-ethyl)- amino substituted compound in the middle of scheme 1 on page 36, see examples 1-7; the 6-chloro-N4-(2-methoxy-ethyl)amino substituted compound in the middle of scheme 2 on page 38, see examples 8-11. Further examples 91-118 show similar intermediates featuring instead of the 2-methoxy-ethyl group in the N4-(2-methoxy-ethyl)amino substituent the following groups: 2-ethoxy-ethyl, 2-isopropoxy-ethyl, 2-n-propoxy-ethyl, 2-t-butoxy-ethyl, 3-methoxy-propyl, 3-ethoxy-propyl and 2-methoxy-butyl;; claim 1 *;
	[Y]* US2013029982 (CASTRO ALFREDO C [US], et al) [Y] 1-102 * tables 3, 4; compounds 1-36,38,40,57,59,74,75,78-92,94,101-103 *;
	[Y]* US2012122838 (REN PINGDA [US], et al) [Y] 1-102 * example 154; compound 238 *;
	[Y]* WO2013060881 (VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG [NL]) [Y] 1-102 * Tables on pages 32 and 34;; claims 4, 5, 10 *;
	[X]* WO2006050843 (HOFFMANN LA ROCHE [CH], et al) [X] 1,3-20,63-71 * Compound XIII of example 6; Quinazoline starting compounds of examples 33, 48 and 73;; claim 29 *;

[X] ➤ [EP0042593](#) (BOEHRINGER MANNHEIM GMBH [DE]) [X] 1,3-20,63-71 * 2nd compound on page 14; page 14 *;

[X] ➤ [EP0322133](#) (SMITHKLINE BECKMAN INTERCREDIT [NL]) [X] 1,3-20,63-71 * examples 2, 4, 6; claim - *;

[X] ➤ [JP2000053653](#) (SUMITOMO PHARMA, et al) [X] 1,3-20,63-71 * Compound depicted on page 5, paragraph 44 & all compounds depicted on pages 10-11 *;

[X] ➤ [JP2000053654](#) (SUMITOMO PHARMA, et al) [X] 1,3-20,63-71 * Compounds depicted in paragraphs 58, 62, 63, 68 etc. as given on pages 11-14 etc. *;

[X] ➤ [US5064833](#) (IFE ROBERT J [GB], et al) [X] 1,3-20,63-71 * examples 1-4, 6, 7, 11, 18, 25, etc.; claims 1-6 *;

[X] - PING YIN ET AL, "Synthesis of 2,4-Diaminoquinazolines and Tricyclic Quinazolines by Cascade Reductive Cyclization of Methyl N-Cyano-2-nitrobenzimidates", THE JOURNAL OF ORGANIC CHEMISTRY, US, (20120316), vol. 77, no. 6, doi:10.1021/jo2023697, ISSN 0022-3263, pages 2649 - 2658, XP055287925 [X] 1,3-20,63-71 * compounds 4a-d, 4f, 4i-p, 4s *

DOI: ➤ <http://dx.doi.org/10.1021/jo2023697>

[X] - CHAPMAN N ET AL, "Synthetic Antimalarials. Part XVI. 4-Dialkylaminoalkylaminoquinazolines. Variation of Substituents in the 6- and 7-Positions", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, (19470101), ISSN 0368-1769, pages 890 - 899, XP008144812 [X] 1,3-20,63-71 * Compounds XII, in particular the one prepared by the method given on page 898, 3rd paragraph from bottom *

USPTO

uspto final 0/0 ^ v x help MyUSPTO

Public Patent Application Information Retrieval

Patent eBusiness

- Electronic Filing
- Patent Application Information (PAIR)
- Patent Ownership
- Fees
- Supplemental Resources & Support

Patent Application Information Retrieval

- Global Dossier
- Order Certified Application As Filed
- Order Certified File Wrapper
- View Order List

15/059,070 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS 1108.P2C JP

Select New CaseApplication DataTransaction HistoryImage File WrapperPatent Term AdjustmentsContinuity DataFeesPublished DocumentsAddress & Attorney/AgentAssignmentsDisplay References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
12-06-2017	NS70	Communication - Re: Power of Attorney (PTOL-308)	PROSECUTION	1	☐
12-01-2017	PA..	Power of Attorney	PROSECUTION	2	☐
12-01-2017	R3.73	Assignee showing of ownership per 37 CFR 3.73	PROSECUTION	3	☐
12-01-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
05-17-2017	ISSUE.NTF	Issue Notification	PROSECUTION	1	☐
04-25-2017	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1	☐
04-25-2017	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
04-25-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
04-11-2017	NOA	Notice of Allowance and Fees Due (PTOL-85)	PROSECUTION	8	☐

EPOQUENET



Europäisches Patentamt
European Patent Office
Office européen des brevets

New connection on: : 27-11-2018 : 01:28:39 - Last disconnection on: : 26-11-2018 : 21:56:42

V 4.0.0.44803(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201820)) (RPM

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 1] ..FI EPODOC



Database: EPODOC

Records: 111.503.842

Terms: 1.475.608.917

Occurrences: 22.556.394.045

Last Update: 20181125

[EPODOC: SS 1] HEPATITIS AND B AND VIRAL AND INFECTION

Results in EPODOC **575**

[SS 2] TOLL AND LIKE AND RECEPTOR

Results in EPODOC **2.145**

[SS 3] 1 AND 2

Results in EPODOC **0**

[SS 4] 1 AND (TOLL+)

Results in EPODOC **1**

[SS 5] ..li ti ab pn




1/1 © EPODOC / EPO

TI - MODULATORS OF **TOLL**-LIKE RECEPTORS

AB - Provided are compounds of Formula Ia:
pharmaceutically acceptable salts thereof,
compositions containing such compounds,
and such compounds for use in the
treatment of a **hepatitis B viral infection**.

PN - [EP3210982](#) A1 20170830

Formula II



[SS 5]